CHRONIC HEPATIT C TREATMENT WITH INTERFERON ALPHA 2b-RIBAVIRIN COMBINATION THERAPY

Key Points

• Patients showed a significant decrease in viral load during combination therapy with interferon alpha 2b and ribavirin.
• A notable reduction in hepatitis C persistence was observed within a 24-week treatment timeframe.
• Combination therapy involves using both interferon alpha 2b and ribavirin to enhance treatment efficacy against hepatitis C.
• Treatment emphasizes the importance of ongoing management for chronic hepatitis C, requiring further validation in diverse populations.